Breo Ellipta Approval History

• FDA approved: Yes (First approved May 10th, 2013)
• Brand name: Breo Ellipta
• Generic name: fluticasone and vilanterol
• Company: GlaxoSmithKline plc (GSK) and Theravance, Inc.
• Treatment for: COPD

Breo Ellipta (fluticasone and vilanterol) is a once-a-day inhaled corticosteroid/long-acting beta2 agonist (LABA) combination indicated for the treatment of patients with chronic obstructive pulmonary disease (COPD).

FDA Approval History for Breo Ellipta

Date	Article
May 10, 2013	FDA Approves Breo Ellipta to Treat Chronic Obstructive Pulmonary Disease (COPD)
Apr 17, 2013	FDA Advisory Committee Recommends Approval of Breo Ellipta for the Treatment of COPD
Sep 26, 2012	GSK and Theravance Announce FDA Acceptance of FF/VI New Drug Application (NDA) Submission in the US for COPD

See also...

Breo Ellipta (fluticasone and vilanterol) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.